Duloxetine in adults with ADHD: a randomized, placebo-controlled pilot study

Area of Science:

• Psychiatry
• Pharmacology

Background:

• Adult Attention-Deficit/Hyperactivity Disorder (ADHD) is a prevalent neurodevelopmental disorder.
• Pharmacological interventions are crucial for managing ADHD symptoms in adults.

Purpose of the Study:

• To evaluate the efficacy of duloxetine in treating adult ADHD.
• To assess duloxetine's impact on ADHD symptom severity and clinical global impression.

Main Methods:

• A 6-week, double-blind, placebo-controlled trial involving 30 adult ADHD patients.
• Participants received either duloxetine 60 mg daily or a placebo.
• Symptom severity was measured using the Conners' Adult ADHD Rating Scale (CAARS) and Clinical Global Impression Scales (CGI).

Main Results:

• Duloxetine significantly reduced CGI-Severity scores (p < .001) and improved CGI-Improvement scores (p < .001) compared to placebo.
• Duloxetine led to greater decreases in five of eight CAARS subscales.
• No significant effects were observed on Hamilton Anxiety Rating Scale (HARS) or Hamilton Depression Rating Scale (HDRS) scores.

Conclusions:

• Duloxetine demonstrates potential as a therapeutic option for adult ADHD.
• Further research with larger sample sizes is warranted to confirm these findings.